Xeris (XERS) Q4 2025: Recorlev Patient Base Doubles, Unlocking 44% Revenue Surge

2026-03-02 | By EarningsIQ Research

Xeris Biopharma’s fourth quarter capped a transformative year, with Recorlev, rare disease therapy, nearly doubling its patient base and fueling outsized revenue growth. Management’s conviction in self-sustainability and pipeline advancement is now matched by financial results, as the company pivots to strategic investment in commercial and R&D scale. The 2026 outlook signals confidence in both commercial momentum and blockbuster pipeline potential, with execution risk shifting to operational scaling and IP defense.

Summary

• Recorlev Expansion Drives Growth: Commercial team doubled, patient base nearly doubled, setting up sustained adoption tailwind.
• Margin Structure Strengthens: Gross margin reached 85% for the year, benefiting from favorable product mix and disciplined expense management.
• Pipeline Inflection Approaches: XP8121 phase 3 initiation in late 2026 marks a pivotal milestone for future growth and value creation.

Performance Analysis

Xeris delivered 44% full-year revenue growth, reaching $292 million, with Q4 up 43% year over year. The acceleration was broad-based, but Recorlev emerged as the clear engine, more than doubling in revenue and patient count to approximately 700 on therapy. This expansion was underpinned by increased prescriber awareness and a differentiated clinical profile, with Recorlev now accounting for nearly half the company’s revenue base.

GVOKE, the glucagon rescue therapy, grew 14% for the year, maintaining its role as a stable, guideline-aligned product, while Caveas, rare disease therapy, continued to outperform expectations and maintained or increased its patient base despite a small addressable market. Gross margin improved to 85% for the year, reflecting product mix leverage. Adjusted EBITDA reached $59.4 million, and the company reported its first full-year net income, marking a defining shift to financial self-sustainability.

• Recorlev Scale-Up: Commercial expansion and patient support investments are driving rapid adoption and will continue to be a growth lever.
• Operating Leverage Emerges: Revenue growth outpaced expense increases, with SG&A up 12% and R&D up 22% as pipeline investment ramps.
• Portfolio Durability: All three commercial products contributed, reinforcing a more resilient revenue base and reducing reliance on any single asset.

While Recorlev’s performance is the headline, Xeris’ disciplined expense management and margin expansion signal a business model transition from capital-raising to self-funding, setting up for greater strategic flexibility in the coming years.

Executive Commentary

Strategic Positioning

1. Recorlev Commercial Scale and IP Defense

Recorlev, Xeris’ therapy for endogenous Cushing’s syndrome, remains the primary growth engine, with the patient base nearly doubling in 2025 and a major commercial team expansion in January 2026. Management expects continued investment in sales and patient support to be necessary as the patient load grows. The company is also vigorously defending its intellectual property, filing lawsuits against ANDA (Abbreviated New Drug Application, generic drug approval pathway) filers and highlighting four Orange Book patents valid through 2040 plus orphan drug exclusivity through 2028. This dual focus on commercial execution and IP protection is intended to sustain Recorlev’s growth trajectory toward a $1 billion peak sales target by 2035.

2. Portfolio Diversification and Margin Profile

GVOKE and Caveas, though smaller, provide stability and incremental growth, with GVOKE benefiting from broad access and treatment guideline alignment, and Caveas demonstrating resilience in a niche rare disease market. The product mix shift toward higher-margin therapies has steadily improved gross margin, with management targeting “best in class” margin profiles as the portfolio matures.

3. Pipeline Leverage: XP8121 as Next Blockbuster

XP8121, a once-weekly subcutaneous levothyroxine for hypothyroidism, is positioned as the next major value driver, with phase 3 initiation slated for the second half of 2026. Management is deliberately scaling up R&D and device manufacturing to ensure a smooth transition to pivotal trials, aiming to address a 3 to 5 million patient U.S. subpopulation with GI absorption issues. The company’s conviction in XP8121’s $1-3 billion peak sales potential underpins its capital allocation strategy.

4. Capital Allocation and Self-Funding Model

Xeris is now operating from a position of financial strength, with adjusted EBITDA positivity expected to persist even as R&D and SG&A rise. Leadership emphasized discipline in both internal investments and external business development, noting that while M&A or partnerships are possible, there is no immediate need given the strength of the current portfolio and pipeline.

5. Litigation and Competitive Landscape

Patent litigation is viewed as a manageable, long-term process, with management expressing high confidence in the durability of Recorlev’s IP. The risk from generic entrants is downplayed, with the company emphasizing the clinical differentiation and referral process required for Recorlev therapy. Competitive activity is not expected to materially disrupt the growth trajectory.

Key Considerations

Xeris’ 2025 results and 2026 guidance reflect a business at an inflection point, shifting from survival mode to strategic scale. Investors should focus on the durability of Recorlev’s growth, the operational execution of the expanded commercial footprint, and the pipeline’s transition from promise to value realization.

Key Considerations:

• Recorlev’s Expansion Investment: Ongoing increases in sales and patient support spending are expected as adoption scales, with management signaling further resource additions in coming years.
• Margin Sustainability: Product mix improvements have lifted gross margin, but continued SG&A and R&D investment will test operating leverage as the company scales.
• Pipeline Execution Risk: XP8121’s phase 3 launch depends on device and formulation scale-up, with regulatory alignment achieved but operational milestones outstanding.
• IP Litigation Timeline: Patent defense for Recorlev is in early stages, with multiyear timelines and outcome uncertainty, though management expresses strong confidence in its position.
• Capital Allocation Flexibility: Self-funding status provides optionality for disciplined external business development, but no urgency to diversify beyond current assets.

Risks

Key risks include execution on commercial scaling, particularly as Recorlev’s patient management complexity rises, and the potential for protracted or adverse IP litigation outcomes. Pipeline advancement depends on successful device and formulation work for XP8121, with delays potentially pushing out value realization. Competitive dynamics in rare disease and endocrinology markets remain a background risk, though management currently sees limited direct threat from generics or new entrants.

Forward Outlook

For 2026, Xeris guided to:

• Total revenue of $375 million to $390 million, representing over 30% growth at the midpoint.
• Adjusted EBITDA positive for the year, with absolute dollar growth over 2025 despite higher R&D and SG&A.

For full-year 2026, management maintained a focus on:

• Expanding Recorlev adoption through increased commercial investment.
• Initiating XP8121 phase 3 in the second half, with a $25 million R&D step-up.
• Further gross margin improvement from product mix, with stable gross-to-net dynamics expected.

Leadership highlighted that the impact of the commercial expansion should be most visible in the second half of 2026 and beyond, and that the company remains positioned for continued self-funding and disciplined investment.

Takeaways

Xeris’ 2025 results mark a structural shift to financial self-sufficiency and operational scale, with Recorlev’s rapid adoption and margin expansion providing the platform for pipeline investment and optionality.

• Recorlev’s Doubling Patient Base: The commercial expansion and IP defense are fundamental to sustaining growth and reaching the $1 billion sales target.
• Pipeline Transition Risk: XP8121’s phase 3 readiness is a key 2026 milestone; operational execution and device scale-up are the next gating items.
• Margin and Capital Allocation Discipline: Management’s focus on margin improvement and self-funding enables flexibility, but rising SG&A and R&D will test the model as investment ramps.

Conclusion

Xeris enters 2026 with clear momentum, a durable commercial foundation, and a pipeline approaching pivotal value creation milestones. Execution on commercial scaling and pipeline advancement will determine whether the company can translate its self-sustaining model into sustained long-term growth and shareholder value.

Industry Read-Through

Xeris’ performance and strategic pivot reinforce the importance of commercial execution and IP durability for specialty pharma and rare disease players. The rapid scaling of Recorlev’s patient base, paired with disciplined margin management, offers a blueprint for transitioning from capital-dependent to self-funded growth. The company’s approach to pipeline advancement—delaying phase 3 until device and formulation are market-ready—highlights the operational discipline increasingly expected in the sector. For peers, the focus on portfolio durability, gross margin optimization, and capital allocation discipline are instructive as the industry faces intensifying competition and cost pressures.

XERS Healthcare Pharmaceuticals Rare Disease Product Launch Pipeline Intellectual Property Margin Expansion